Annual FCF
-$18.45 M
+$25.72 M+58.23%
December 31, 2023
Summary
- As of February 12, 2025, QNCX annual free cash flow is -$18.45 million, with the most recent change of +$25.72 million (+58.23%) on December 31, 2023.
- During the last 3 years, QNCX annual FCF has risen by +$32.42 million (+63.73%).
- QNCX annual FCF is now -86.31% below its all-time high of -$9.90 million, reached on December 31, 2017.
Performance
QNCX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$7.31 M
+$1.47 M+16.77%
September 30, 2024
Summary
- As of February 12, 2025, QNCX quarterly free cash flow is -$7.31 million, with the most recent change of +$1.47 million (+16.77%) on September 30, 2024.
- Over the past year, QNCX quarterly FCF has dropped by -$1.20 million (-19.73%).
- QNCX quarterly FCF is now -244.14% below its all-time high of -$2.12 million, reached on September 30, 2018.
Performance
QNCX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$30.58 M
-$2.49 M-8.86%
September 30, 2024
Summary
- As of February 12, 2025, QNCX TTM free cash flow is -$30.58 million, with the most recent change of -$2.49 million (-8.86%) on September 30, 2024.
- Over the past year, QNCX TTM FCF has dropped by -$12.13 million (-65.72%).
- QNCX TTM FCF is now -862.48% below its all-time high of -$3.18 million, reached on March 31, 2018.
Performance
QNCX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
QNCX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.2% | -19.7% | -65.7% |
| 3 y3 years | +63.7% | -19.7% | -65.7% |
| 5 y5 years | -55.0% | -19.7% | -65.7% |
QNCX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +70.8% | -97.2% | +54.6% | -67.4% | +53.4% |
| 5 y | 5-year | at high | +70.8% | -97.2% | +58.6% | -67.4% | +53.4% |
| alltime | all time | -86.3% | +70.8% | -244.1% | +58.6% | -862.5% | +53.4% |
Quince Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.31 M(-16.8%) | -$30.58 M(+8.9%) |
| Jun 2024 | - | -$8.78 M(+4.6%) | -$28.09 M(+21.4%) |
| Mar 2024 | - | -$8.39 M(+37.5%) | -$23.14 M(+25.4%) |
| Dec 2023 | -$18.45 M(-58.2%) | -$6.10 M(+26.7%) | -$18.45 M(+1.0%) |
| Sep 2023 | - | -$4.82 M(+25.9%) | -$18.26 M(-9.6%) |
| Jun 2023 | - | -$3.83 M(+3.3%) | -$20.19 M(-36.5%) |
| Mar 2023 | - | -$3.71 M(-37.3%) | -$31.78 M(-28.1%) |
| Dec 2022 | -$44.17 M(-30.0%) | -$5.91 M(-12.4%) | -$44.17 M(-16.2%) |
| Sep 2022 | - | -$6.75 M(-56.2%) | -$52.72 M(-16.7%) |
| Jun 2022 | - | -$15.41 M(-4.2%) | -$63.31 M(-3.4%) |
| Mar 2022 | - | -$16.10 M(+11.3%) | -$65.56 M(+3.9%) |
| Dec 2021 | -$63.11 M | -$14.46 M(-16.6%) | -$63.11 M(+1.9%) |
| Sep 2021 | - | -$17.34 M(-1.8%) | -$61.94 M(+8.7%) |
| Jun 2021 | - | -$17.66 M(+29.4%) | -$56.98 M(+6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$13.65 M(+2.7%) | -$53.73 M(+5.6%) |
| Dec 2020 | -$50.87 M(+52.6%) | -$13.29 M(+7.2%) | -$50.87 M(+4.8%) |
| Sep 2020 | - | -$12.39 M(-14.0%) | -$48.54 M(+7.9%) |
| Jun 2020 | - | -$14.41 M(+33.6%) | -$44.97 M(+22.0%) |
| Mar 2020 | - | -$10.78 M(-1.6%) | -$36.85 M(+10.6%) |
| Dec 2019 | -$33.33 M(+179.9%) | -$10.96 M(+24.2%) | -$33.33 M(+26.5%) |
| Sep 2019 | - | -$8.82 M(+40.4%) | -$26.35 M(+34.1%) |
| Jun 2019 | - | -$6.28 M(-13.5%) | -$19.65 M(+22.8%) |
| Mar 2019 | - | -$7.27 M(+82.9%) | -$16.00 M(+34.3%) |
| Dec 2018 | -$11.91 M(+20.2%) | -$3.97 M(+87.1%) | -$11.91 M(+50.1%) |
| Sep 2018 | - | -$2.12 M(-19.4%) | -$7.93 M(+36.5%) |
| Jun 2018 | - | -$2.63 M(-17.1%) | -$5.81 M(+82.9%) |
| Mar 2018 | - | -$3.18 M | -$3.18 M |
| Dec 2017 | -$9.90 M | - | - |
FAQ
- What is Quince Therapeutics annual free cash flow?
- What is the all time high annual FCF for Quince Therapeutics?
- What is Quince Therapeutics annual FCF year-on-year change?
- What is Quince Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Quince Therapeutics?
- What is Quince Therapeutics quarterly FCF year-on-year change?
- What is Quince Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Quince Therapeutics?
- What is Quince Therapeutics TTM FCF year-on-year change?
What is Quince Therapeutics annual free cash flow?
The current annual FCF of QNCX is -$18.45 M
What is the all time high annual FCF for Quince Therapeutics?
Quince Therapeutics all-time high annual free cash flow is -$9.90 M
What is Quince Therapeutics annual FCF year-on-year change?
Over the past year, QNCX annual free cash flow has changed by +$25.72 M (+58.23%)
What is Quince Therapeutics quarterly free cash flow?
The current quarterly FCF of QNCX is -$7.31 M
What is the all time high quarterly FCF for Quince Therapeutics?
Quince Therapeutics all-time high quarterly free cash flow is -$2.12 M
What is Quince Therapeutics quarterly FCF year-on-year change?
Over the past year, QNCX quarterly free cash flow has changed by -$1.20 M (-19.73%)
What is Quince Therapeutics TTM free cash flow?
The current TTM FCF of QNCX is -$30.58 M
What is the all time high TTM FCF for Quince Therapeutics?
Quince Therapeutics all-time high TTM free cash flow is -$3.18 M
What is Quince Therapeutics TTM FCF year-on-year change?
Over the past year, QNCX TTM free cash flow has changed by -$12.13 M (-65.72%)